Lorlatinib
![]() |
- ₹0
- Product name: Lorlatinib
- CAS: 1454846-35-5
- MF: C21H19FN6O2
- MW: 406.41
- EINECS:813-704-5
- MDL Number:
- Synonyms:(10R)-7-Amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile;Lorlatinib,PF-06463922;PF-06463922, Lorlatinib;(R)-26-amino-55-fluoro-11,4,7-trimethyl-6-oxo-11H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-15-carbonitrile;Lorlatinib(PF0643922);High Purity API Lorlatinib;Anaplastic lymphoma kinase (ALK);Lorlatinib Powder
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :184-187°C
Boiling point :675.0±55.0 °C(Predicted)
Density :1.42±0.1 g/cm3(Predicted)
storage temp. :Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility :Chloroform (Slightly), Ethyl Acetate (Slightly)
form :Solid
pka :6.05±0.40(Predicted)
color :White to Off-White
Stability :Hygroscopic
InChI :InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
InChIKey :IIXWYSCJSQVBQM-LLVKDONJSA-N
SMILES :[C@@H]1(C)C2=CC(F)=CC=C2C(=O)N(C)CC2=NN(C)C(C#N)=C2C2C=C(C(N)=NC=2)O1
Boiling point :675.0±55.0 °C(Predicted)
Density :1.42±0.1 g/cm3(Predicted)
storage temp. :Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility :Chloroform (Slightly), Ethyl Acetate (Slightly)
form :Solid
pka :6.05±0.40(Predicted)
color :White to Off-White
Stability :Hygroscopic
InChI :InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
InChIKey :IIXWYSCJSQVBQM-LLVKDONJSA-N
SMILES :[C@@H]1(C)C2=CC(F)=CC=C2C(=O)N(C)CC2=NN(C)C(C#N)=C2C2C=C(C(N)=NC=2)O1
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||
Precautionary statements: |
|
Description
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that promotes cell proliferation and blocks apoptosis. PF-06463922 is an ATP-competitive, selective inhibitor of ALK (Ki = < 0.07 nM) and c-Ros oncogene 1 (ROS1, Ki = 0.7 nM). It has strong activity against all known ALK and ROS1 mutants identified in patients, including the EML4-L1196M mutant of ALK (Ki = < 0.02 nM). PF-06463922 is orally available, displaying inhibition of ALK phosphorylation and antitumor efficacy in a xenograft model expressing EML4-L1196M ALK. It demonstrates efficient blood-brain barrier penetration, produces brain tumor regression in mice harboring EML4-ALK tumors, and increases overall survival.More related product prices
Oclacitinib 1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol Chidamide Imatinib Lenvatinib Crizotinib BAY 87-2243 1469337-95-8 Cabozantinib Ceritinib (LDK378) AP26113 Brigatinib BKM120 (NVP-BKM120, Buparlisib) INCB28060 NVP-TAE684 - TAE 684 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one PF-06447475 PF-06650833 PF-06700841 tosylate 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dioneRelated product price
- Imatinib
₹5100-26800 - Crizotinib
₹13174.03 - BAY 87-2243
₹7760-31350